Literature DB >> 15117171

Premenstrual dysphoric disorder: a review for the treating practitioner.

Gurjit Kaur1, Lilian Gonsalves, Holly L Thacker.   

Abstract

Premenstrual dysphoric disorder (PMDD), a severe form of premenstrual syndrome (PMS), is characterized by physical and behavioral symptoms that cause marked social impairment during the last half of the menstrual cycle. Symptoms are believed to result from the interaction of central neurotransmitters and normal menstrual hormonal changes. Treatment usually begins with lifestyle changes, over-the-counter medications, and if needed, selective serotonin reuptake inhibitors. Physicians should be aware of the risks of many of the alternative therapies commonly touted in the popular press.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15117171     DOI: 10.3949/ccjm.71.4.303

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN: 0891-1150            Impact factor:   2.321


  6 in total

1.  The complexity of premenstrual dysphoric disorder--risk factors in the population of Polish women.

Authors:  Violetta Skrzypulec-Plinta; Agnieszka Drosdzol; Krzysztof Nowosielski; Ryszard Plinta
Journal:  Reprod Biol Endocrinol       Date:  2010-11-14       Impact factor: 5.211

Review 2.  Drospirenone/ethinylestradiol 3mg/20microg (24/4 day regimen): a review of its use in contraception, premenstrual dysphoric disorder and moderate acne vulgaris.

Authors:  Caroline Fenton; Keri Wellington; Marit D Moen; Dean M Robinson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Premenstrual syndrome and comorbid depression among medical students in the internship stage: a descriptive study.

Authors:  Seyed Saeed Sadr; Seyed Mehdi Samimi Ardestani; Katayoon Razjouyan; Mahboobeh Daneshvari; Ghazal Zahed
Journal:  Iran J Psychiatry Behav Sci       Date:  2014

4.  Prevalence, impacts and medical managements of premenstrual syndrome among female students: cross-sectional study in College of Health Sciences, Mekelle University, Mekelle, northern Ethiopia.

Authors:  Fikru Wakjira Tolossa; Mebratu Legesse Bekele
Journal:  BMC Womens Health       Date:  2014-03-29       Impact factor: 2.809

5.  Beta-Arrestin1 Levels in Mononuclear Leukocytes Support Depression Scores for Women with Premenstrual Dysphoric Disorder.

Authors:  Farzana Alam; Sanket Nayyar; William Richie; Anthony Archibong; Tultul Nayyar
Journal:  Int J Environ Res Public Health       Date:  2015-12-22       Impact factor: 3.390

Review 6.  Contraceptive options for women with premenstrual dysphoric disorder: current insights and a narrative review.

Authors:  Iñaki Lete; Oihane Lapuente
Journal:  Open Access J Contracept       Date:  2016-08-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.